In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI ...

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and ...

However, the panel notes that "For those who are not eligible for these shorter regimens, the 2016 and 2019 recommendations should be consulted." Using the thorough, evidence-based Grading of ...

Researchers identified three new all-oral drug regimens that include at least one of two new drugs for treatment of rifampin-resistant tuberculosis, according to a study. The study tested five all ...

A synthetic chronogenetic gene circuit for programmed circadian drug delivery - ...

Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline ...